



Attorney's Docket No. 33339/176332

RECEIVED  
FEB 07 2003  
PATENT  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Guy Serre et al. Confirmation No.: 6404  
Appl. No.: 09/254,032 Group Art Unit: 1653  
Filed: April 26, 1999 Examiner: L. Mayes  
For: ANTIGENS DERIVED FROM FILAGGRIN  
AND THEIR USE FOR DIAGNOSING  
RHEUMATOID POLYARTHRITIS

Commissioner for Patents  
Washington, DC 20231

RECEIVED  
MAR 13 2003  
TECH CENTER 1600/2900

Sir:

Transmitted herewith is an AMENDMENT in the above-identified patent application.

- ☐ Applicant claims small entity status. See 37 C.F.R. § 1.27.  
☐ No additional fee is required.

The fee has been calculated as shown below:

(COL. 1)		(COL. 2)	(COL. 3)	SMALL ENTITY		OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	OR RATE	ADDIT. FEE
TOTAL	* 29	** 22	= 7	X9=	\$	X18=	\$ 126
INDEP	* 2	*** 3	=	X42=	\$	X84=	\$
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				+140=	\$	+280=	\$
				TOTAL ADD FEE \$		OR TOTAL	\$ 126

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior Amendment or the number of claims originally filed.

In re: Guy Serre et al.  
Appl. No.: 09/254,032  
Filed: April 26, 1999  
Atty. Dock. No. 33339/176332  
Page 2

- ☐ Please charge my Deposit Account No. 16-0605 in the amount of \$
- ☒ A check in the amount \$126.00 to cover the additional fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge any deficiency in payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-0605.
- ☒ Any additional filing fees required under 37 C.F.R. § 1.16 for the presentation of extra claims.
- ☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,



Melissa B. Pendleton  
Registration No. 35,459  
Attorney/Agent of Record

**RECEIVED**

MAR 13 2003

TECH CENTER 1600/290

CUSTOMER NO. 00826  
**ALSTON & BIRD LLP**  
Bank of America Plaza  
101 South Tryon Street, Suite 4000  
Charlotte, NC 28280-4000  
Tel Charlotte Office (704) 444-1000  
Fax Charlotte Office (704) 444-1111

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on January 22, 2003.



Grace R. Rippy



Attorney's Docket No. 33339/176332

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Guy Serre et al.  
Appl. No.: 09/254,032  
Filed: April 26, 1999  
For: ANTIGENS DERIVED FROM FILAGGRIN  
AND THEIR USE FOR DIAGNOSING  
RHEUMATOID POLYARTHRITIS

Confirmation No.: 6404  
Group Art Unit: 1653  
Examiner: L. Mayes

*[Signature]*  
PATENT  
FEB 07 2003  
RECEIVED  
TECH CENTER 1600/2900  
3/18/03

January 22, 2003

Commissioner for Patents  
Washington, DC 20231

AMENDMENT

Sir:

Please amend the above-referenced application as follows:

RECEIVED  
MAR 13 2003  
TECH CENTER 1600/2900

In The Claims:

01  
1. (Twice amended) An artificial antigen which is specifically recognized by the antifilaggrin autoantibodies present in the serum of patients suffering from rheumatoid arthritis, which consists of a recombinant or synthetic polypeptide having at least one citrulline residue, wherein said polypeptide is derived from a filaggrin unit selected from SEQ ID NO: 7 or a fragment thereof having at least 5 consecutive amino acids comprising at least one arginine residue.

Sub E1  
2. (Twice amended) The artificial antigen as claimed in claim 1, wherein said fragment of at least 5 consecutive amino acids of a filaggrin unit is selected from:  
fragment 144 to 314 of SEQ ID NO: 7 or sub-fragments thereof comprising at least one arginine residue; and

fragment 76 to 144 of SEQ ID NO: 7 or sub-fragments thereof comprising at least one arginine residue.

01/30/2003 AOSMAN1 00000060 09254032

01 FC:1202

126.00 0P